
The enterprise software sector is experiencing a significant sell-off due to AI fears, creating a potential buying opportunity in high-quality names like Adobe (ADBE) that are being unfairly punished. In the weight-loss drug market, consider favoring winner Eli Lilly (LLY), which is executing flawlessly, over Novo Nordisk (NVO) as it faces significant pricing and market share challenges. Google's (GOOGL) stock dip, caused by massive AI spending plans, may represent a buying opportunity for investors with a long-term horizon of at least three years. Finally, aggressive AI infrastructure spending by tech giants serves as a strong bullish signal for key suppliers like NVIDIA (NVDA).

By @theprofgpod
NYU Professor, best-selling author, business leader and serial entrepreneur Scott Galloway cuts through the biggest stories in ...